Klaria Pharma Holding Year-End Report
Additions to the management team and structural changes to prepare for an increased focus on clinical development and out-licensingFOURTH QUARTER (OCTOBER–DECEMBER) ∞ Net sales amounted to 0.2 MSEK (0.0 MSEK) ∞ R&D costs for the period amounted to 9.7 MSEK (7.2 MSEK) ∞ Profit after tax amounted to -5.3 MSEK (-8.1 MSEK) ∞ Earnings per share for the quarter amounted to -0.17 SEK (-0.26 SEK) ∞ Cash flow from operating activities amounted to -5.7 MSEK (-2.9 MSEK) ∞ Cash and cash equivalents on the balance day amounted to 2.9 MSEK (8,0 MSEK) ∞ Shareholder’s equity per